Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation agreement with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), securing exclusive commercialization rights for Austedo (deutetrabenazine) in mainland China.
Austedo, a vesicle monoamine transporter 2 (VMAT2) inhibitor, received its initial approval in the U.S. in 2017 and was later approved in China in 2020 for the treatment of tardive dyskinesia (TD) associated with Huntington’s disease (HD) in adults. The drug was also included in the National Reimbursement Drug List (NRDL) that same year.
As part of the agreement, Nhwa will make an upfront payment of USD 10 million along with a subsequent licensing fee of USD 20 million. The company is required to achieve cumulative sales of between RMB 2 billion and RMB 2.5 billion from 2024 to 2028.- Flcube.com
